TY - JOUR T1 - Early clinical trials in paediatric oncology in Spain: A nationwide perspective JO - Anales de Pediatría (English Edition) T2 - AU - Bautista,Francisco AU - Gallego,Soledad AU - Cañete,Adela AU - Mora,Jaume AU - Díaz de Heredia,Cristina AU - Cruz,Ofelia AU - Fernández,José María AU - Rives,Susana AU - Berlanga,Pablo AU - Hladun,Raquel AU - Juan Ribelles,Antonio AU - Madero,Luis AU - Ramírez,Manuel AU - Fernández Delgado,Rafael AU - Pérez-Martínez,Antonio AU - Mata,Cristina AU - Llort,Anna AU - Martín Broto,Javier AU - Cela,María Elena AU - Ramírez,Gema AU - Sábado,Constantino AU - Acha,Tomás AU - Astigarraga,Itziar AU - Sastre,Ana AU - Muñoz,Ascensión AU - Guibelalde,Mercedes AU - Moreno,Lucas SN - 23412879 M3 - 10.1016/j.anpede.2016.07.007 DO - 10.1016/j.anpede.2016.07.007 UR - https://analesdepediatria.org/en-early-clinical-trials-in-paediatric-articulo-S2341287917301345 AB - IntroductionCancer is the leading cause of death between the first year of life and adolescence, and some types of diseases are still a major challenge in terms of cure. There is, therefore, a major need for new drugs. Recent findings in cancer biology open the door to the development of targeted therapies against individual molecular changes, as well as immunotherapy. Promising results in adult anti-cancer drug development have not yet been translated into paediatric clinical practice. A report is presented on the activity in early paediatric oncology trials (phase I–II) in Spain. Material and methodsAll members of the Spanish Society of Paediatric Haematology Oncology (SEHOP) were contacted in order to identify early clinical trials in paediatric cancer opened between 2005 and 2015. ResultsA total of 30 trials had been opened in this period: 21 (70%) in solid tumours, and 9 (30%) in malignant haemopathies. A total of 212 patients have been enrolled. The majority was industry sponsored (53%). Since 2010, four centres have joined the international consortium of Innovative Therapies for Children with Cancer (ITCC), which has as its aim to develop novel therapies for paediatric tumours. A significant number of new studies have opened since 2010, improving the treatment opportunities for our children. Results of recently closed trials show the contribution of Spanish investigators, the introduction of molecularly targeted agents, and their benefits. ConclusionsThe activity in clinical trials has increased in the years analysed. The SEHOP is committed to develop and participate in collaborative academic trials, in order to help in the advancement and optimisation of existing therapies in paediatric cancer. ER -